Scientists have developed new DNA vaccine for vascular endothelial growth factor (VEGF) that could prolong survival in cancer and can improve cancer treatment strategies.
Vascular endothelial growth factor (VEGF):
VEGF is a protein produced by cells to activate formation of blood vessels. This process helps in restoring the oxygen supply to the tissues in case of improper blood circulation. Although, it is a good process but in case of cancer, it is deadly as it provides oxygen to cancerous cells helping them to grow and spread.
Bevacizumab is an anticancer drug that slows the growth of new blood vessels and in this way we can say that bevacizumab is an anti-VEGF drug.
In the present study, scientists developed new DNA vaccine for VEGF using Hepatits B virus core (HBc) system and used against VEGF in mouse having cancer. “HBc protein was used as an epitope carrier to enhance the immunogenicity.” Scientists worked on vaccine allowing it activate humoral immunity without altering cellular immunity for VEGF.
They found that the vaccine reduced the growth of new blood vessels resulting in prolonged survival in mouse. “Overall, the present data first provided the potential activity to inhibit angiogenesis in cancer models, oxygen-induced retinopathy and laser-induced CNV models using DNA VEGF vaccine,” Researchers wrote.
According to scientists, this therapeutic strategy has relatively low cost and less treatment schedule as opposed to the present treatments of anti-VEGF/VEGFR antibodies such as the use of Bevacizumab.
You can work on the efficacy of the combination of VEGF DNA vaccination and chemotherapy or immunotherapy against cancer. Moreover, therapeutic model, which is mouse in this case, can also be changed for efficacy and modifications of this VEGF DNA vaccine can also be done to optimize efficacy.
Mariko Kyutoku et al. (2013). Development of novel DNA vaccine for VEGF in murine cancer model Scientific Reports DOI: 10.1038/srep03380